Significant effects of antiretroviral therapy on global gene expression in brain tissues of patients with HIV-1-associated neurocognitive disorders
- PMID: 21909266
- PMCID: PMC3164642
- DOI: 10.1371/journal.ppat.1002213
Significant effects of antiretroviral therapy on global gene expression in brain tissues of patients with HIV-1-associated neurocognitive disorders
Abstract
Antiretroviral therapy (ART) has reduced morbidity and mortality in HIV-1 infection; however HIV-1-associated neurocognitive disorders (HAND) persist despite treatment. The reasons for the limited efficacy of ART in the brain are unknown. Here we used functional genomics to determine ART effectiveness in the brain and to identify molecular signatures of HAND under ART. We performed genome-wide microarray analysis using Affymetrix U133 Plus 2.0 Arrays, real-time PCR, and immunohistochemistry in brain tissues from seven treated and eight untreated HAND patients and six uninfected controls. We also determined brain virus burdens by real-time PCR. Treated and untreated HAND brains had distinct gene expression profiles with ART transcriptomes clustering with HIV-1-negative controls. The molecular disease profile of untreated HAND showed dysregulated expression of 1470 genes at p<0.05, with activation of antiviral and immune responses and suppression of synaptic transmission and neurogenesis. The overall brain transcriptome changes in these patients were independent of histological manifestation of HIV-1 encephalitis and brain virus burdens. Depending on treatment compliance, brain transcriptomes from patients on ART had 83% to 93% fewer dysregulated genes and significantly lower dysregulation of biological pathways compared to untreated patients, with particular improvement indicated for nervous system functions. However a core of about 100 genes remained similarly dysregulated in both treated and untreated patient brain tissues. These genes participate in adaptive immune responses, and in interferon, cell cycle, and myelin pathways. Fluctuations of cellular gene expression in the brain correlated in Pearson's formula analysis with plasma but not brain virus burden. Our results define for the first time an aberrant genome-wide brain transcriptome of untreated HAND and they suggest that antiretroviral treatment can be broadly effective in reducing pathophysiological changes in the brain associated with HAND. Aberrantly expressed transcripts common to untreated and treated HAND may contribute to neurocognitive changes defying ART.
Conflict of interest statement
The authors have declared that no competing interests exist.
Figures






Similar articles
-
Systems analysis of human brain gene expression: mechanisms for HIV-associated neurocognitive impairment and common pathways with Alzheimer's disease.BMC Med Genomics. 2013 Feb 13;6:4. doi: 10.1186/1755-8794-6-4. BMC Med Genomics. 2013. PMID: 23406646 Free PMC article.
-
Transcriptomic analysis of brain tissues identifies a role for CCAAT enhancer binding protein β in HIV-associated neurocognitive disorder.J Neuroinflammation. 2020 Apr 11;17(1):112. doi: 10.1186/s12974-020-01781-w. J Neuroinflammation. 2020. PMID: 32276639 Free PMC article.
-
Neuro-immune deconvolution analysis of OAS3 as a transcriptomic central node in HIV-associated neurocognitive disorders.J Neurol Sci. 2023 Mar 15;446:120562. doi: 10.1016/j.jns.2023.120562. Epub 2023 Jan 20. J Neurol Sci. 2023. PMID: 36706688
-
When do models of NeuroAIDS faithfully imitate "the real thing"?J Neurovirol. 2018 Apr;24(2):146-155. doi: 10.1007/s13365-017-0601-5. Epub 2017 Dec 18. J Neurovirol. 2018. PMID: 29256039 Free PMC article. Review.
-
Antiretroviral medications disrupt microglial phagocytosis of β-amyloid and increase its production by neurons: implications for HIV-associated neurocognitive disorders.Mol Brain. 2011 Jun 7;4(1):23. doi: 10.1186/1756-6606-4-23. Mol Brain. 2011. PMID: 21649911 Free PMC article. Review.
Cited by
-
HIV-induced neuroinflammation inhibits oligodendrocyte maturation via glutamate-dependent activation of the PERK arm of the integrated stress response.Glia. 2021 Sep;69(9):2252-2271. doi: 10.1002/glia.24033. Epub 2021 May 31. Glia. 2021. PMID: 34058792 Free PMC article.
-
Systems Biology Analysis of the Antagonizing Effects of HIV-1 Tat Expression in the Brain over Transcriptional Changes Caused by Methamphetamine Sensitization.Viruses. 2020 Apr 9;12(4):426. doi: 10.3390/v12040426. Viruses. 2020. PMID: 32283831 Free PMC article.
-
HIV induces expression of complement component C3 in astrocytes by NF-κB-dependent activation of interleukin-6 synthesis.J Neuroinflammation. 2017 Jan 26;14(1):23. doi: 10.1186/s12974-017-0794-9. J Neuroinflammation. 2017. PMID: 28122624 Free PMC article.
-
Common transcriptional signatures in brain tissue from patients with HIV-associated neurocognitive disorders, Alzheimer's disease, and Multiple Sclerosis.J Neuroimmune Pharmacol. 2012 Dec;7(4):914-26. doi: 10.1007/s11481-012-9409-5. Epub 2012 Oct 12. J Neuroimmune Pharmacol. 2012. PMID: 23065460 Free PMC article. Review.
-
Mechanisms underlying HIV-associated cognitive impairment and emerging therapies for its management.Nat Rev Neurol. 2023 Nov;19(11):668-687. doi: 10.1038/s41582-023-00879-y. Epub 2023 Oct 10. Nat Rev Neurol. 2023. PMID: 37816937 Free PMC article. Review.
References
-
- Chang L, Ernst T, Leonido-Yee M, Witt M, Speck O, et al. Highly active antiretroviral therapy reverses brain metabolite abnormalities in mild HIV dementia. Neurology. 1999;53:782–789. - PubMed
-
- Robertson KR, Robertson WT, Ford S, Watson D, Fiscus S, et al. Highly active antiretroviral therapy improves neurocognitive functioning. J Acquir Immune Defic Syndr. 2004;36:562–566. - PubMed
-
- Robertson KR, Smurzynski M, Parsons TD, Wu K, Bosch RJ, et al. The prevalence and incidence of neurocognitive impairment in the HAART era. AIDS. 2007;21:1915–1921. - PubMed
-
- Sacktor N, McDermott MP, Marder K, Schifitto G, Selnes OA, et al. HIV-associated cognitive impairment before and after the advent of combination therapy. J Neurovirol. 2002;8:136–142. - PubMed
Publication types
MeSH terms
Substances
Grants and funding
- R21 NS061646/NS/NINDS NIH HHS/United States
- R01DA017618/DA/NIDA NIH HHS/United States
- R24 MH059724/MH/NIMH NIH HHS/United States
- P01 NS031492/NS/NINDS NIH HHS/United States
- R24MH59724/MH/NIMH NIH HHS/United States
- P01NS31492/NS/NINDS NIH HHS/United States
- U01MH083501/MH/NIMH NIH HHS/United States
- R01MH083627/MH/NIMH NIH HHS/United States
- U01 MH083501/MH/NIMH NIH HHS/United States
- U01 MH083545/MH/NIMH NIH HHS/United States
- R01 DA017618/DA/NIDA NIH HHS/United States
- R21NS061646/NS/NINDS NIH HHS/United States
- R01 MH083627/MH/NIMH NIH HHS/United States
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Molecular Biology Databases